Search - tctmd.com

Displaying 1 - 20 of 63

Sort: Relevancy | Date

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Todd Neale

November 13, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Todd Neale

November 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Todd Neale

August 28, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

Advertisement

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Most Patient-Reported Outcome Measures in CVD Fall Short

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Good News and Bad for High-Intensity Statin Use in ASCVD

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content